These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 17514771

  • 1. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
    Kalpadakis C, Pangalis GA, Dimopoulou MN, Vassilakopoulos TP, Kyrtsonis MC, Korkolopoulou P, Kontopidou FN, Siakantaris MP, Dimitriadou EM, Kokoris SI, Tsaftaridis P, Plata E, Angelopoulou MK.
    Hematol Oncol; 2007 Sep; 25(3):127-31. PubMed ID: 17514771
    [Abstract] [Full Text] [Related]

  • 2. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
    Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, Kokoris SI, Dimitriadou EM, Dimopoulou MN, Moschogiannis M, Korkolopoulou P, Kyrtsonis MC, Siakantaris MP, Papadaki T, Tsaftaridis P, Plata E, Papadaki HE, Vassilakopoulos TP.
    Oncologist; 2013 Sep; 18(2):190-7. PubMed ID: 23345547
    [Abstract] [Full Text] [Related]

  • 3. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
    Bennett M, Schechter GP.
    Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
    [Abstract] [Full Text] [Related]

  • 4. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
    Cervetti G, Galimberti S, Pelosini M, Ghio F, Cecconi N, Petrini M.
    Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
    [Abstract] [Full Text] [Related]

  • 5. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
    Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ.
    Cancer; 2006 Jul 01; 107(1):125-35. PubMed ID: 16700034
    [Abstract] [Full Text] [Related]

  • 6. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).
    Cervetti G, Galimberti S, Sordi E, Buda G, Orciuolo E, Cecconi N, Petrini M.
    Ann Oncol; 2010 Apr 01; 21(4):851-854. PubMed ID: 19825880
    [Abstract] [Full Text] [Related]

  • 7. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R.
    J Clin Oncol; 2000 Sep 01; 18(17):3135-43. PubMed ID: 10963642
    [Abstract] [Full Text] [Related]

  • 8. Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
    Bennett M, Yegena S, Dave HP, Schechter GP.
    Hematol Oncol; 2008 Jun 01; 26(2):114. PubMed ID: 18271062
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C.
    Br J Haematol; 2018 Dec 01; 183(5):755-765. PubMed ID: 30407629
    [Abstract] [Full Text] [Related]

  • 10. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
    Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F.
    Blood; 1998 Sep 15; 92(6):1927-32. PubMed ID: 9731049
    [Abstract] [Full Text] [Related]

  • 11. Splenic marginal zone lymphoma: disease features and management.
    Matutes E.
    Expert Rev Hematol; 2013 Dec 15; 6(6):735-45. PubMed ID: 24168526
    [Abstract] [Full Text] [Related]

  • 12. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
    Else M, Marín-Niebla A, de la Cruz F, Batty P, Ríos E, Dearden CE, Catovsky D, Matutes E.
    Br J Haematol; 2012 Nov 15; 159(3):322-8. PubMed ID: 23016878
    [Abstract] [Full Text] [Related]

  • 13. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
    Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel B, Muellauer L, Der-Petrossian M, Jonak C, Binder M, Raderer M.
    Ann Oncol; 2009 Feb 15; 20(2):326-30. PubMed ID: 18836086
    [Abstract] [Full Text] [Related]

  • 14. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
    Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A, Qin J, Teruya-Feldstein J, Portlock CS.
    Cancer J; 2002 Feb 15; 8(5):371-6. PubMed ID: 12416894
    [Abstract] [Full Text] [Related]

  • 15. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma.
    Bieker R, Kessler T, Berdel WE, Mesters RM.
    Oncol Rep; 2003 Feb 15; 10(6):1915-7. PubMed ID: 14534718
    [Abstract] [Full Text] [Related]

  • 16. Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.
    Drapkin R, Di Bella NJ, Faragher DC, Harden E, Matei C, Hyman W, Mirabel M, Boehm KA, Asmar L.
    Clin Lymphoma; 2003 Dec 15; 4(3):169-75. PubMed ID: 14715099
    [Abstract] [Full Text] [Related]

  • 17. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
    Leahy MF, Seymour JF, Hicks RJ, Turner JH.
    J Clin Oncol; 2006 Sep 20; 24(27):4418-25. PubMed ID: 16940276
    [Abstract] [Full Text] [Related]

  • 18. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
    Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, Arcache J, Callet-Bauchu E, Salles G, Coiffier B.
    Clin Lymphoma; 2002 Jun 20; 3(1):41-7. PubMed ID: 12141954
    [Abstract] [Full Text] [Related]

  • 19. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V.
    Ann Oncol; 1999 Jun 20; 10(6):655-61. PubMed ID: 10442187
    [Abstract] [Full Text] [Related]

  • 20. [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
    Miztani M, Noda T, Umino A, Tanigawa M, Taniguchi M, Tamaki S, Tsuji K.
    Rinsho Ketsueki; 2007 Nov 20; 48(11):1489-91. PubMed ID: 18080507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.